Objectives. To identify contributing factors associated with inactive disease (ID) and clinical remission for patients with juvenile idiopathic arthritis (JIA) treated with etanercept.
Introduction
Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children, where the term JIA means a group of clinically heterogeneous arthritides, which begin before the age of 16 years, are of unknown cause, and persist for >6 weeks [1, 2] . The incidence of JIA in the West is estimated at 10-19 cases/100 000 children and the prevalence at 400/100 000 children [3, 4] .
The aetiology is still not well understood whereby genetic as well as environmental factors seem to play a role [5] . The prognosis is problematic because many children are still suffering from active disease courses as adults. This may cause joint damage, persistent pain and retardation of normal growth, which eventually may lead to long-term disability and decreased quality of life [6] .
The traditional treatment of children with JIA consisted of NSAIDs, corticosteroids (CSs) and disease-modifying anti-rheumatic drugs (DMARDs) such as MTX, but all these drugs are effective only in a limited number of patients [7] . Progress in the investigaton of the pathogenesis has resulted in the development of new drugs, the biologics, which have enhanced the available treatment options. Biologics are genetically engineered drugs that work by selectively blocking the effects of cytokines, which play an important role in the inflammatory process. In many cases, this induces complete control of disease activity and remission, respectively, and helps to prevent long-term joint damage.
Currently, etanercept, a TNF-a antagonist, is the best evaluated biologic for the treatment of JIA. Following the favourable results of a placebo-controlled, randomized trial using the pediatric American College of Rheumatology (PedACR) criteria [8, 9] , etanercept was approved in Europe in 2000 for the treatment of children ages 4-17 years with refractory, polyarticular JIA.
Due to the improved treatment options, remission can be regarded as the new objective of therapy even for patients with RA. However, as different definitions of remission exist worldwide, which are used inconsistently [10] [11] [12] , it is necessary to establish more precise, homogenous criteria before evaluating remission. Currently, these requirements seem to be best fulfilled by the definition of Wallace et al. [13] .
Patients and methods
The German Etanercept Registry is an ongoing, long-term, multicentre, prospective open-label observational study that was started in 2001 [14] . The ethical committee of the Martin-Luther University Halle-Wittenberg and ethical committee of the Aerztekammer Nordrhein at Duesseldorf approved the registry. Written consent was obtained from the subject's parents according to the Declaration of Helsinki. JIA patients age 4-17 years with at least one follow-up form after initiation of treatment were included in the analysis of inactive disease (ID) (n = 787); and for the evaluation of clinical remission on medication (CRM), provided that the required duration of follow-up periods had been appropriately reached [13] . All patients had suffered from long-standing, refractory disease and had been previously treated with NSAIDs and either CSs or MTX (or both).
Patients were assessed before the initiation of etanercept and at 3, 6 and 12 months and then every 6 months thereafter. Treatment with MTX or other DMARDs was permitted and documented in the follow-up forms. Despite NSAIDs, MTX (n = 567) and CSs (n = 365) were the most frequently administered concomitant treatments. During registration, 29 patients were receiving concomitantly IA shots of triamcinolone hexacetonid, 45 patients were treated with AZA, 12 patients with (OH-)chloroquine, 3 patients with mycophenolate mofetil (MMF), 29 patients with SSZ, 37 patients with ciclosporin and 13 patients with LEF.
Criteria for ID and remission
Generally, all effectiveness data were compared with the corresponding baseline data. The effectiveness of treatment was evaluated using the remission criteria of Wallace et al. [13] . The following definitions were made: 'No active synovitis' was defined as no active arthritis according to the PedACR definition [8] .
'No fever, rash, serositis, splenomegaly or generalized lymphadenopathy attributable to JIA' indicating ID in systemic-onset JIA (soJIA) patients could not be directly evaluated. Since these signs and symptoms are unlikely to be observed in soJIA patients with normal levels of CRP and ESR, we decided to use these laboratory parameters instead. 'Normal ESR or CRP' was defined as ESR 4 20 mm/h and CRP 4 10 mg/l. 'Physician's global assessment of disease activity indicating no active disease' was defined as a value 410 mm on a 100-mm visual analogue scale (VAS). 'No active uveitis' was defined as no signs of uveitis as derived from the documentation of adverse events. According to the criteria proposed by Wallace et al. [13] , ID requires all the above-mentioned criteria, while CRM is defined as a period of six continuous months of ID on medication. The presence or the extent of psoriasis or enthesitis has not been documented in the registry and as a limitation, the presence of uveitis is recorded if it is registered as an adverse event.
The frequency of patients with ID or CRM in patients with JIA on treatment with etanercept was calculated using the data of the German Etanercept Registry. In addition, the potential association of several baseline characteristics [e.g. age, sex, age at onset of disease, disease duration before initiation of etanercept, concomitant medication, disease activity parameters, number of active joints, duration of morning stiffness, pain, parents' global assessment of overall well-being, physicians' global assessment of disease activity, disability as measured by the childhood HAQ (CHAQ) and ESR] with these treatment outcomes was investigated.
In addition to the proposed criteria by Wallace et al. [13] , modified criteria have been used for some calculations, including the parent's global assessment of overall well-being taken from the CHAQ score indicating no active disease, defined as a value of 410 mm on a 100-mm VAS, and patients' global assessment of pain indicating no actual pain, defined as a value of 410 mm on a 100-mm VAS.
Statistical analysis
Demographic and other baseline characteristics at enrolment were listed descriptively. The data were analysed using the U-test, chi-square test, odds ratio (OR) and logistic regression. Time to remission (i.e. ID) was calculated using Kaplan-Meier estimates for the patient's duration of treatment.
Results
The data for 787 patients treated with etanercept were available. The patients' characteristics (Tables 1 and 2) indicated long mean disease duration before initiation of treatment. A high disease activity was indicated by high numbers of active joints and high levels of parents' and physicians' global assessment of disease activity. The majority of patients (64.5%) were girls. The JIA category distribution is outlined in Table 2 . Data indicated polyarticular involvement in the majority of patients; only 5% of the patients had persistent oligoarticular JIA. Seventy-five per cent of patients received MTX at the initiation of www.rheumatology.oxfordjournals.org etanercept therapy and 45.9% received CSs. Further concomitant treatment is given in Table 2 .
Overall, a total of 4898 follow-up forms for 787 JIA patients were evaluated. Twenty per cent of forms had incomplete data sets within the parameters, weekly dose of etanercept, CRP, ESR, physician's and patient's VAS, and active joint count, which therefore could not be used for ID analysis. A total of 375 (47.6%) patients reached the criteria for ID and 166 (26.6%) patients for CRM.
ID
Patients with ID had a statistically significant shorter disease duration before starting etanercept (4.6 vs 5.6 years; P = 0.008) and received a higher weekly dosage related to weight (0.9 vs 0.86 mg/kg; P = 0.045) and body surface (28.0 vs 26.8 mg/m 2 ; P = 0.045). At the start of therapy they had a lower active joint count (7.6 vs 10.2; P = 0.001) and a lower CHAQ score (0.77 vs 0.95; P = 0.01; Table 1 ). All characteristics varied significantly (P < 0.001) among the JIA categories, except the weekly dosage (in milligrams per kilogram; P = 0.4). Of note, patients receiving concomitant treatment with MTX had higher disease activity indicators compared with those not receiving MTX, and those receiving concomitant treatment with CSs also had a significantly higher disease activity compared with those not receiving CSs (Table 3) . The analysis of the ORs showed that an initial concomitant MTX medication raised the relative chance of achieving ID, especially in seropositive polyarthritis (OR = 2.0; P = 0.03, Table 4 ). Furthermore, it seemed that patients with concomitant CS medication had a reduced chance for ID (OR = 0.7; P = 0.03). Girls had a proportionally lower chance to reach ID than boys (OR = 0.73; P = 0.049).
These results were mostly confirmed by the logistic regression: the regression coefficients eb for age of onset (P = 0.026) and disease duration were 0.9 (P = 0.01), for the active joint count 0.97 (P = 0.002) and for the CHAQ score 0.77 (P = 0.03). Thus, higher values in these characteristics impaired the chance of reaching ID because eb < 1 expresses a negative correlation.
Upon Kaplan-Meier analysis the probability of ID was 25% after 6 months of therapy, 50% after 15.5 months and 75% after 48 months. Patients starting treatment with etanercept within 2 years after diagnosis achieved ID at a significantly higher rate (Fig. 1) .
ID was reached by patients with extended oligoarticular JIA more often and more rapidly than by patients with seronegative polyarthritis. Fewer patients with seropositive polyarthritis and with systemic arthritis reached ID and needed a longer time of treatment, as outlined in Fig. 2A . The observed differences between the categories in reaching ID were statistically significant.
The patients eligible for the analysis of ID were additionally analysed by modified criteria including parents' global assessment of overall well-being and patients' assessment of pain. When using these modified remission criteria, the number of responders decreased from 375 to 98 patients, which means a loss of 75% of patients. Excluding the assessment of patients' pain from the analysis, only four (1%) responders were lost. This indicated not only a high concordance of the physicians' to the parents' global assessment of overall well-being, but it also suggested that the patients' pain is neglected by the original criteria.
CRM
For the evaluation of CRM, 623 JIA patients who had a minimum period of 12 months' follow-up were included in the analysis. Overall, 177 (26.6%) patients reached CRM. Patients achieving the CRM criteria had a significantly shorter disease duration before starting etanercept, received a higher weekly dosage related to body weight and body surface, and had a lower active joint count and a lower CHAQ score at baseline than those patients who failed ( Table 1 ). The mean values for the characteristics listed above varied significantly between the categories of JIA (P = 0.001) except for the weekly dosage (in milligrams per kilogram; P = 0.2) and the CHAQ score (P = 0.9).
The OR of the relation female/male was 0.68 (95% CI 0.47, 0.98; P = 0.04). Girls had a lower chance of achieving CRM than boys. The OR for reaching CRM for patients who started treatment within 2 years after onset of the disease compared with those who started treatment later was 1.77 (95% CI 1.19, 2.64; P = 0.05; Table 4 ). Thus patients with a disease duration of <2 years before starting etanercept had a higher chance of reaching remission on medication in comparison with the longer diseased patients. The logistic regression result showed that an increase of the particular value of 1 U changes the chance for remission multiplicatively with the following factors eb: age of disease onset 0.9 (P = 0.02), disease duration 0.8 (P = 0.01) and active joint count 1.0 (P = 0.025). According to the Kaplan-Meier analysis, the probability of remission on medication was 25% after 28 months of therapy and 50% after 75 months. CRM was also more rapidly reached by patients starting treatment within 2 years (Fig. 1) . CRM was reached by patients with seropositive polyarthritis less frequently and was delayed when compared with the categories extended oligoarticular JIA, seronegative polyarthritis and systemic arthritis (Fig. 2B) .
Of those patients reaching remission on ongoing medication with etanercept (CRM), 24% received concomitant treatment with MTX alone; 20% received MTX + NSAIDs; 12% received MTX + CSs + NSAIDs; 6% received NSAIDs + other DMARDs; and 3% each received MTX + CSs, CSs + NSAIDs, other DMARDs plus CSs + NSAIDs or other DMARDs only; and 1% received other DMARDs + CSs. Only 11% of the patients received exclusively etanercept. Due to smaller numbers compared with the ID analysis, there was no statistically significant difference in concomitant treatment between those patients reaching CRM and those not reaching CRM.
Discussion
The analysed 787 patients formed the largest group of JIA patients treated with etanercept that has been described so far. Although it was not a criterion for inclusion, the majority of patients in the German Etanercept Registry had a polyarticular or systemic disease course and all had previously been treated with either CSs or MTX (or both), so that there is limited comparability of these results with other clinical trials [15] [16] [17] . Even if there was no control group and a limited comparability to randomized controlled trials (RCTs), our study provides valuable information about the magnitude of effects, relative to the findings of the RCT of Lovell et al. [9] . The advantages of the registry data used for this study are (i) timely unlimited long-term observation, (ii) a representative and lessselected study population and (iii) a reflection of the real-life setting in effectiveness and compliance [14, 18] . A problematic issue with registry data could be the fact that a distinct treatment regimen is only recommended, but not mandatory. Individual changes (e.g. of the weekly dosage), which are qualitatively documented but could not be evaluated or quantified in their variability, may have had negative effects on the long-term outcome.
Under the real-life conditions, the data of the ID analysis showed a high initial effectiveness of etanercept in JIA which, in some patients, was only achieved after a longer period of treatment. Until now, due to smaller patient numbers, there has been no other trial that could evaluate remission of the disease for all categories of JIA. However, the early but so far only existing RCT in JIA patients treated with etanercept showed a rapid and marked improvement [9] . In this study, after 3 months of [15] [16] [17] . All studies reported substantial improvements of symptoms under etanercept therapy. The consistency and the large magnitude of the treatment effects across these uncontrolled studies are in agreement with the beneficial outcome of our analysis and support the general effectiveness of etanercept for the treatment of JIA. In these studies, some predictive factors could be evaluated which, however, were not significant or just sporadically significant in these few and small trials [9, 15, [19] [20] [21] [22] . Our results, based on a large number of patients, showed that male gender, early initiation of etanercept, a less severe disease course, as well as adherence to or even exceedance of the recommended weekly dosage increased the chance of complete control of disease activity. This has been noted already through clinical observations, but statistical evidence was missing until now. Patients with shorter disease duration, less severe disease and male gender have a greater chance for ID. Therefore, effective treatment should be offered within a suitable period of time, which seems to be during the first 2 years of the disease.
According to the outcomes of other trials, patients with the soJIA subset reached ID with lower frequency, even if a good outcome in some patients was achieved. MTX, which had been used successfully as concomitant medication before [18] , increased the relative chance of reaching ID in this study as well, especially in patients with seronegative polyarthritis. Of note, patients receiving concomitant treatment with MTX had higher disease indicators at the start of etanercept than those not receiving MTX.
Until now there were no studies investigating remission on medication for all categories of JIA. Even in the real-life setting, this analysis showed a high and long-lasting effectiveness of etanercept for a determined patient group under constant therapy. The observations supported the results from former trials with small patient numbers [17, 19] . In the Dutch National Registry [15] , remission on medication was observed in 36% of the patients. But in some patients, etanercept seems to have no or only short-lasting positive effects, even if clinical improvement according to PedACR is achievable and enduring for the majority of patients. Again, male gender, early initiation of etanercept and less severe disease course support remission on medication, which is the same effect as for ID. The initial weekly dosage was not associated with remission on medication, perhaps because of variable and individual modifications during the therapy course. The same applies-perhaps for the same reason-for the initially concomitant medication of MTX and CSs. Other observations show that a long-term combination of etanercept and MTX has positive effects on the outcome and leads to a sustained clinical improvement in a significant number of patients [20, 21] . Unfortunately, for the other evaluated predictive factors, very little data exist for comparison because they were not evaluated or showed no significance due to the small numbers of patients described [15, [19] [20] [21] [22] . The discussion about a general, standardized definition of remission in JIA is recent, and the latest consensus still has to prove its validity as well as its prognostic significance during long-term implementation.
When using modified remission criteria, including the patients' global assessment of pain, the number of responders in ID decreased markedly. Thus a normalization of the laboratory inflammation parameters and the disappearance of clinical symptoms do not necessarily mean a subjective sensation of absence of all symptoms, especially of pain. In the current definitions of remission, the patients' pain is excluded [13] . The reason for this exclusion may have been the fact that it cannot be clearly determined to what extent pain is due to damage occurring after a longer disease duration (which cannot be influenced by anti-inflammatory agents), or due to ongoing inflammation indicating ongoing active disease. On the other hand, it seems that the parents' global assessment of overall well-being is congruent with the physicians' assessment, so that its additional evaluation does not seem necessary. The described difficulty of the different current concepts of remission is, therefore, still not fully resolved with the dispersion of the Wallace criteria.
Rheumatology key messages
. In JIA patients, ID and remission can be frequently reached upon treatment with etanercept. . Patients with shorter disease duration, less severe disease and male gender have a higher chance for ID. . The recommended dosage of etanercept, 0.8 mg/kg weekly, and concomitant treatment with MTX are of value.
